Aug-18-17 Antibe Therapeutics Announces Closing of Public Offering
Aug-02-17 Antibe Therapeutics Receives Approval to Initiate Phase 2 Gastrointestinal Endoscopy Clinical Trial
Jul-28-17 Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results
Jun-21-17 Antibe Therapeutics Announces Closing of Public Offering
Jun-15-17 Antibe Therapeutics Announces Filing of Final Short Form Prospectus
May-26-17 Antibe Therapeutics Announces Pricing of Offering
May-24-17 Antibe Therapeutics Announces Proposed Offering of Units
May-12-17 Antibe Therapeutics Engages Topstone Research and Appoints Dr. Francis Chan as Key Advisor for Phase 2 Clinical Trial of ATB-346
Apr-26-17 Antibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic
Apr-24-17 Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference
Apr-18-17 Antibe Therapeutics Provides Update on Clinical Development Program for its Lead Drug, ATB-346
Mar-31-17 Antibe Therapeutics Announces Grant of Stock Options
Mar-27-17 Antibe’s Founder and Chief Scientific Officer to Receive Distinguished Lifetime Achievement Award in Research
Mar-07-17 Antibe Therapeutics Announces Results of Annual General Meeting
Mar-01-17 Antibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results
Feb-24-17 Antibe Therapeutics Enters into Regional Licensing Deal
Feb-20-17 Antibe Therapeutics Engages MKR Group for U.S. Investor Relations
Jan-31-17 Antibe Therapeutics Announces the Launch of PentOS OI™ Max, its Newest Bone Graft Substitute for Oral and Maxillofacial Surgery
Jan-18-17 Antibe Therapeutics Announces Change of Auditor to Ernst & Young
Dec-21-16 Antibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million